Key Findings

  • mCRC patients with primary tumours originating in the right colon are relatively resistant to standard-of-care systemic chemotherapy regimens and have a worse prognosis1-3
  • Treating these patients with FOLFOX-based chemotherapy + SIRT using SIR-Spheres® Y-90 resin microspheres in first-line resulted in a statistically significant (p<0.008) and clinically meaningful (HR=0.64) improvement in overall survival compared to chemotherapy alone, as demonstrated in a post hoc sub-group analysis4

1. Tejpar S et al.  JAMA Oncol 2017; 3: 194-201.
2. Petrelli F et al. JAMA Oncol 2017; 3: 211–19.
3. Venook AP et al. Proc Am Soc Clin Oncol 2016; 34 (suppl 15): 3504 (abstr).
4. Gibbs P et al.  Clin Col Cancer 2018 Jun 12 ePub: doi: 10.1016/j.clcc.2018.06.001.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage